University of Texas System

Georg-august-universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin

Georg-august-universität Göttingen Stiftung Öffentichen Rechts, Universitätsmadizin

Georg-august-universitat Gottingen Stiftung Offentlichen Rechts, Universitatsmedizin

Georg-august-universitat Gottingen Stiftung Offentlichen Rechts

Michael Zeisberg

Raghu Kalluri

Elisabeth Zeisberg

Gerhard Anton Mueller

Désiree Tampe

Bjoern Tampe

Björn Tampe

Edgar Voss

Gerd Hasenfuss

Xingbo Xu

Xu Xingbo

Xiaoying Tan

Gunsmaa Nyamsuren

Lutz Tietze Friedjahn

Shyam Sundar Mothuku

Miriam Puls

Karl Toischer

Claudius Jacobshagen

The present disclosure is directed to novel therapeutic approaches for the prevention, treatment and/or delaying progression of chronic injury, progressive loss of functional parenchymal cells, or fibrosis of an organ. Specifically disclosed are agents for use in increasing homodimer-formation of ARNT in an organ in the prevention, treatment and/or delaying progression of chronic injury, progressive loss of functional parenchymal cells, or fibrosis of said organ, as further defined in the claims. In embodiments, said agent may be (i) an inhibitor of protein phosphatase 2A (PP2A) activity, (ii) an inhibitor of the transcriptional repressor complex FKBP12/YY1, or (iii) an expression construct, which is capable of over-expressing ARNT in said organ, as well as combinations of (i), (ii), and/or (iii).

Prevention or treatment of chronic organ injury

Provided is a method of preventing, treating or delaying progression of a disease involving aberrant fibroblast proliferation. The method involves using a compound that reduces the level of tyrosine phosphatase activity effected by the protein EYA1A in the parenchymal organ, a nucleic acid ligase IV inhibitor, or an antisense oligonucleotide against the p53-binding protein 1 (53BP1).

Treatment of aberrant fibroblast proliferation

Growing community of inventors

Goettingen, Germany

Michael Zeisberg